Navigation Links
Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary
Date:7/30/2010

SAN DIEGO, July 30 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were not disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology.

Conatus Pharmaceuticals is led by Steven J. Mento, Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The addition of Idun to Conatus continues our important work in liver disease and expands our therapeutic reach into oncology," said Dr. Mento.  "Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology."

Idun Pharmaceuticals was a privately-held biopharmaceutical company engaged in the discovery and development of drug candidates to control apoptosis. At the time of the acquisition by Pfizer, Idun had a Phase 2 drug candidate in liver disease (emricasan/IDN-6556), preclinical drug candidates including IDN-13389 for oncology, a development agreement with Abbott for an oncology drug candidate, and key intellectual property in the field of apoptosis.  Conatus' SVP Corporate Development, Jennifer Giottonini Cayer added, "We appreciate the contributions of Pfizer's colleagues on these potentially important drug candidates.  Conatus is excited to have the opportunity to work on these programs."  

Conatus Pharmaceuticals Inc. is a privately-held pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. The lead drug candidate, CTS-1027 is in multiple Pha
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
2. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
3. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
4. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
5. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
6. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
7. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
8. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
9. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... Anemia is a condition that occurs when red ... properly. When an individual has anemia, the body does not ...
(Date:8/27/2014)... , Aug. 27, 2014  CVS Caremark (NYSE: ... a new clinical affiliation with MedStar Health, a leading ... Maryland and the Washington, DC ... affordable health care services for patients. Through this clinical ... to clinical support, medication counseling, chronic disease monitoring and ...
(Date:8/27/2014)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its third quarter of fiscal 2014: For ... Revenue of $1,291,378, a 13% decrease over the same period ... quarter of $240,156 compared to net income of $238,826 during ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... Calif., Oct. 1 Accuray Incorporated (Nasdaq: ARAY ... announced today publication of results from a study of ... The study demonstrated that erectile function was preserved in ... two years. Published rates of erectile function preservation at ...
... Systems, a Hill-Rom company, (NYSE: HRC ), announces ... with top orthopaedic surgeons. Carlos A. Guanche, M.D., managing ... surgeon and is recognized for his contributions in expanding ... elbow fractures, scopes and clavicle repair procedures. , ...
Cached Medicine Technology:Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 2Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 3Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 4Allen Medical Systems Announces Surgeon Spotlight Series Interview 2Allen Medical Systems Announces Surgeon Spotlight Series Interview 3
(Date:8/27/2014)... (PRWEB) August 27, 2014 For nearly ... performances by the beloved mantra singers Deva Premal & ... Following the release of their latest album in May, ... down in twenty-two countries around the globe, including Russia, ... Argentina and across Europe. With a new album and ...
(Date:8/27/2014)... BESLER Consulting , a leading provider ... is pleased to announce that it has been named ... Companies. The list represents the most comprehensive look at ... , "It's been an exciting year for our company ... year's Inc. 5000 list,” said Jonathan Besler, BESLER’s President ...
(Date:8/27/2014)... August 27, 2014 Home Care ... care for seniors, is proud to announce the next ... upcoming webinar will feature Dr. Suzanne Steinbaum, attending cardiologist ... Hospital in New York City, National Spokesperson for the ... webinar will cover the issues surrounding women and heart ...
(Date:8/27/2014)... clinical trial participation in the largest ongoing observational study ... not representative of the larger patient base, according to ... Jay Udell. The study authors call into question the ... and suggest the use of broader enrollment criteria and ... know that clinical trials can be tremendously expensive and ...
(Date:8/27/2014)... (Lebanon, NH 8/27/14)Dartmouth cancer researchers developed and tested ... and environmental interactions that contribute to disease as ... , The approach fills a gap in ... from complex interactions among genetic and environmental factors. ... relevant interactions versus those that reflect chance combinations ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... study, there is a connection between certain bacteria in ... of using probiotics to treat autism.// ... this study. Though the results are very preliminary, he ... propose any link between autism and childhood vaccinations. ...
... of medical tourism has created new vistas, enabling a ... world.// In the race for being the best in ... the industry’s powerful trident - Pharmaceutical Industry, Doctors and ... well as diseases”, said Karl Marx, and what better ...
... from Spain are not too comfortable with the outcome of ... grace//, could carry a risk of formation of fatal blood ... 2000 as an upgraded version of bare-metal stents. ... have the drug-lined versions of the stents, which are designed ...
... Attention Deficit Hyperactivity Disorder (ADHD) cannot sit calmly at ... health professionals and parents are familiar with the symptoms, ... topic. ,The FDA has given instructions that ... should put up warnings about the possible side effects ...
... James, the British chairman of the International Obesity Task ... the obesity epidemic in poor countries. ,"The ... which subsidize and distort the market to make fats ... James said at the 10th International Obesity Congress in ...
... 150th anniversary celebrations of Madras University, his alma mater ... institutions in India. ,Speaking on the occasion, ... "Good teaching emanates from research. Any university is judged ... academics here. ,He opened a virtual university ...
Cached Medicine News:Health News:Probiotics – a probable treatment for Autis 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 3Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 4Health News:Alternative therapies for ADHD 2Health News:Alternative therapies for ADHD 3Health News:President Launches Madras University's 150th Year Celebrations 2
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Medicine Products: